Pharmaceutical lawyer John Lisman sets up new practice
This article was originally published in SRA
Executive Summary
Pharmaceutical lawyer John Lisman has left Netherlands-based international law firm NautaDutilh to set up his own legal and consultancy practice. The new practice, Lisman Legal Life sciences BV, based in Nieuwerbrug, aims to bridge the gap between regulatory affairs and legal matters. Mr Lisman plans to cover areas such as: the promotion of innovation; the protection of innovation; unmet medical needs; unchallenged regulatory questions; and medical products of the future.
You may also be interested in...
EU Accelerated Assessment Tracker
Marinus’s ganaxolone has lost its accelerated assessment status mid-review at the European Medicines Agency while Roche’s glofitamab will be fast-tracked once a filing has been made.
EU Accelerated Assessment Tracker
The EU filing for AstraZeneca’s nirsevimab is being reviewed under the accelerated pathway at the European Medicines Agency. Also, Janssen should know by now whether its planned filing for Zejula plus Zytiga will get the same treatment – as should SIFI for its planned Akantior filing.
AZ Secures EU Fast-Tack Review For Nirsevimab
There could be a regulatory decision on AstraZeneca and Sanofi's nirsevimab in the EU in H2 as a result of the European Medicines Agency speeding up its review of the marketing application for the potential new immunization against RSV in all infants.